Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index, and 1 are not checked yet.

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists

Open access
Górriz, José Luis, Soler, María José, Navarro-González, Juan F., García-Carro, Clara, Puchades, María Jesús, D’Marco, Luis, Martínez Castelao, Alberto, Fernández-Fernández, Beatriz, Ortiz, Alberto, Górriz-Zambrano, Carmen, Navarro-Pérez, Jorge, Gorgojo-Martinez, Juan José · 2020 · Journal of Clinical Medicine

Abstract

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm9040947

Cites

72 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Potential mechanisms for the cardio-nephroprotective effect of GLP-1RA (modified from: Thomas [39] and Greco [40].
Figure 1 Potential mechanisms for the cardio-nephroprotective effect of GLP-1RA (modified from: Thomas [39] and Greco [40].CC BY · PubMed Central
Figure 2 GLP-1RA RCT studies with known beneficial cardiovascular endpoints. Blue bars—percentage of 3-point MACE reduction with the intervention drug. Orange bars—percentage of individual primary cardiovascular endpoint reduction with the intervention drug. Three-point MACE, 3-point MACE; MI, fatal and nonfatal myocardial infarction.
Figure 2 GLP-1RA RCT studies with known beneficial cardiovascular endpoints. Blue bars—percentage of 3-point MACE reduction with the intervention drug. Orange bars—percentage of individual primary cardiovascular endpoint reduction with the intervention drug. Three-point MACE, 3-point MACE; MI, fatal and nonfatal myocardial infarction.CC BY · PubMed Central
Figure 3 GLP-1RA RCT studies with known beneficial renal endpoints. Blue bars—percentage of composite renal endpoint reduction with the intervention drug. Orange bars—percentage of individual renal endpoint reduction with the intervention drug. Renal, combined renal endpoint; MA, macroalbuminuria; ↓ eGFR ≥ 40%, Sustained decline in eGFR of ≥40%; ↓ eGFR ≥ 50%, Sustained decline in eGFR of ≥50%.
Figure 3 GLP-1RA RCT studies with known beneficial renal endpoints. Blue bars—percentage of composite renal endpoint reduction with the intervention drug. Orange bars—percentage of individual renal endpoint reduction with the intervention drug. Renal, combined renal endpoint; MA, macroalbuminuria; ↓ eGFR ≥ 40%, Sustained decline in eGFR of ≥40%; ↓ eGFR ≥ 50%, Sustained decline in eGFR of ≥50%.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Research works printed but not linked: 1

  1. 2019, New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus, Hipertens. Riesgo Vasc., 36, 145

Cited by

See all 144

Metadata

Authors
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., Navarro-Pérez, J., & Gorgojo-Martinez, J. J.
Affiliations
  • Universitat de València (ES)
  • Universitat Autònoma de Barcelona (ES)
  • Unidad de Investigación y Servicio de Nefrología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Universidad de La Laguna, 38200 Tenerife, Spain
  • IIS-Fundación Jimenez Diaz UAM and School of Medicine, Universidad Autonoma de Madrid, 28040 Madrid, Spain
  • Nephrology Department, Bellvitge University Hospital, Hospitalet, 08907 Barcelona, Spain
  • CAP Sant Pere, ABS Reus 1, 43202 Tarragona, Spain
  • Unidad de Endocrinología y Nutrición, Fundación Hospital Alcorcón, 28922 Madrid, Spain
Corresponding author
Górriz, José Luis
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2020-03-30
Volume
9
Issue
4
Pages
947
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3014018229
Cited by
144
References
72
Citations by year
2026: 11 · 2025: 18 · 2024: 23 · 2023: 29 · 2022: 38 · 2021: 23 · 2020: 2
FWCI
3.70
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, public-domain)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Hispana (submittedVersion)
Funders
  • Boehringer Ingelheim
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Amicus Therapeutics
  • Fresenius Medical Care North America
  • Novo Nordisk
  • Astellas Pharma
  • Servier
  • Sanofi Genzyme
  • Instituto de Salud Carlos III (RD16/0009, RD16/0009/0022)
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
GLP-1 receptor agonists, diabetic nephropathy, type 2 diabetes, renal protection, glycemic control, macroalbuminuria, glomerular filtration rate decline, renin-angiotensin system inhibitors, proteinuria, weight loss, cardiovascular outcomes, renal replacement therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. https://app.cochat.ai/papers/10.3390/jcm9040947
The paper
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., Navarro-Pérez, J., & Gorgojo-Martinez, J. J. (2020). GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9040947

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.